|
Inpatient Evaluation of Adults with Schizophrenia Clinical Trials Information presented on Clinical Trials Search isn't intended to be a substitute for proven healthcare advice, trips or treatment using a real physician. We are not docs. Always confer with your mD on Inpatient Evaluation of Adults with Schizophrenia conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Inpatient Evaluation of Adults with Schizophrenia Clinical research trials and Inpatient Evaluation of Adults with Schizophrenia medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectiveness of new drugs. The intention of the studies / projects is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector corporations to detect remedies for all forms of circumstances, like Inpatient Evaluation of Adults with Schizophrenia. Inpatient Evaluation of Adults with Schizophrenia Clinical Trials and other clinical trials allow for volunteers to undergo healthcare treatment options before they are available to the masses. Most times the participants receive treatment for free, and every now and again they are paid for their time. Occasionally there is a cost for a Inpatient Evaluation of Adults with Schizophrenia clinical trial. Subjects typically recieve the finest healthcare available for their Inpatient Evaluation of Adults with Schizophrenia condition. Hazards are a reality, nonetheless, and might include more or frequent mD trips, health risks (potentially life-endangering), and/or the treatment being ineffective. Trials are federally regulated with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Inpatient Evaluation of Adults with Schizophrenia  Inpatient Evaluation of Adults with Schizophrenia
Inpatient Evaluation of Adults with Schizophrenia
For Condition: Psychotic Disorder,Schizophrenia,Schizoaffective,Paranoia,Psychosis
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Schizophrenia and related psychoses are chronic brain disorders whose prognosis is often poor and whose pathophysiology remains obscure. Brain imaging technologies such s positron emission tomography (PET), functional magnetic resonance imaging (fMRI), and magnetic resonance imaging (MRI) offer opportunities to study the pathophysiology of psychotic disorders by evaluating brain function. However, the use of anti-psychotic drugs may interfere with the results of such studies. In this study, psychotropic medication will be discontinued in patients for a short period of time to distinguish the effects of the illness on the brain without the interference of the medication's effects on the brain. Given that there is a risk that the patient's symptoms will increase, they are asked to stay on an inpatient unit where the NIMH clinical staff is available to help them 24 hours a day. This study will be conducted in three phases. In Phase 1, participants will be admitted to the Clinical Center while continuing to take their medication and will undergo diagnostic interviews, physical and laboratory assessments, physiological monitoring, and neuropsychological testing. Behavioral ratings will also be performed and blood and urine samples will be collected. During Phase 2, participants will continue taking medications in a blinded fashion for 8 to 12 weeks. The active medications will be replaced with a placebo (an inactive pill) part of that time. PET, fMRI, and MRI scans will be used to monitor how the continuation or lack of medication affects the brain. Psychological tests will also be given to measure changes in cognition. In Phase 3, participants will have the opportunity for clinical stabilization.
Details: Schizophrenia and related psychoses are chronic brain disorders whose prognosis is often poor and whose pathophysiology remains obscure. Neuroimaging technologies such as PET (positron emission tomography), fMRI (functional magnetic resonance imaging), MRSI (magnetic resonance spectroscopic imaging), and SPECT (single photon emission computerized tomography) offer opportunities to elucidate the pathophysiology by studying brain function in living patients. The use of these techniques to study psychotic disorders is severely limited, however, by a critical methodological confound: neuroleptic treatment. The purpose of this protocol is to admit patients with schizophrenia and other related disorders to the Clinical Center, carefully evaluate their neuropsychiatric status, and discontinue psychotropic medications for a brief period so patients can be studied without the confound of neuroleptic treatment. There are several phases to this protocol. The first phase is the evaluation phase and includes gathering historical data, structured diagnostic interviews, general physical and laboratory assessments, basic physiological monitoring, neuropsychological testing, limited collection of blood and urine samples, and serial behavioral ratings. In the second phase, patients will receive blinded compounds that will contain inactive placebo or active neuroleptic administered in a double blind, crossover fashion. Each arm normally lasts 4 to 6 weeks. The total duration of this phase is 8 to 12 weeks. During the coded neuroleptic period, patients are enrolled in a series of neuroimaging and other approved protocols designed to elucidate the neurobiology of these disorders. These include studies using PET, fMRI, MRSI, and SPECT. The neuroleptic free period is essential to distinguish the effects of illness versus medication. Parameters under investigation include traits that are candidate phenotypes for genetic studies and state-dependent aspects of brain function. The combined use of many neuroimaging modalities will allow us to look at the functional relationship between a variety of brain abnormalities hypothesized to play a role in schizophrenia. These include hippocampal neurochemical abnormalities, deficits in prefrontal cortical activation, and dysregulation of subcortical dopamine in a single patient.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Inpatients admitted to the CBDB inpatient program at the Clinical Center must be age 18 or older, either male or female. There is no upper age limit. The primary recruiting emphasis is on patients with schizophrenia, schizoaffective disorder, and psychosis NOS. Subjects with other neuropsychiatric disorders may also be admitted and participate in the protocol if their is sufficient evidence to believethey have an underlying, undiagnosed schizophrenia, schizoaffective disorder, or psychosis NOS. Subjects identified as having major medical problems other than their primary neuropsychiatric disorder will be excluded from admission. Patients judged to be unsuitable for medication free studies will also be excluded. Possible reasons for exclusion include prior history of dangerousness to self or others, particularly when off medication. Because of the long half life of depot medications, applicants to our program are not admitted if they have received a depot injection within 3 months, although exceptions may be made.
Total Enrollment: 325
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting CBDB 3014358970
Additional Information:
Study ID Numbers: 890160; 89-M-0160
Study Start Date: September 13, 1989
Record last reviewed: September 25, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001247
Other Schizophrenia Studies:
1. Glycine to Treat Psychotic Disorders in Children
2. Inpatient Evaluation of Adults with Schizophrenia
3. New Drugs in the Treatment of Mood Disorders
4. Comparison of Clozapine or Olanzapine in Childhood-Onset Psychotic Disorders
5. Genetic Study of Schizophrenia
Related Studies:
Other Schizophrenia Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Inpatient Evaluation of Adults with Schizophrenia
|
|
|
|
|
|
|
|
